Biotech and pharma diversification pays off
25 gen 2024 ·
44 min. 18 sec.
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
https://seekingalpha.com/author/alexander-carchidi?source=ie_podcast:biotech_pharma_diversification_pays_off dissects the biotech sector - mostly highly risky, borderline investments. Diversification pays off (3:40). Funding is hard to come by and performance has not been great but ebb will...
mostra di più
Alex Carchidi dissects the biotech sector - mostly highly risky, borderline investments. Diversification pays off (3:40). Funding is hard to come by and performance has not been great but ebb will give way to flow (6:00). Biotech and pharma; gene editing, gene therapy competitive story (7:45). Buy the rumor, sell the news is cliched but true for these stocks (17:00). Getting realistic about high price of drugs (20:05).
Show Notes:
CRISPR/Vertex gene editing therapy approved in U.S. for beta-thalassemia
First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Lilly, Novo Nordisk diabetes drugs see price raises - report
Episode transcripts
For full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
mostra meno
Show Notes:
CRISPR/Vertex gene editing therapy approved in U.S. for beta-thalassemia
First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Lilly, Novo Nordisk diabetes drugs see price raises - report
Episode transcripts
For full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Informazioni
| Autore | Seeking Alpha |
| Organizzazione | Seeking Alpha |
| Sito | seekingalpha.com |
| Tag |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
Commenti
Brandon Clifford
2 anni fa